2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Adverse Events, Biological Processes, Apoptosis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3547 High response rate and durable remissions following frontline chemotherapy-free treatment with vemurafenib plus obinutuzumab in hairy cell leukemia: Long-term update of a phase II trial

Allison J. Li, MD, PhD, Eric Stephen Winer, MD2, Scott F. Huntington, MD, MPH3, Gottfried von Keudell, MD4, Shreya Vemuri, BSc, MPH5, Madhulika Shukla6, Victoria Duffy7, Steven Gore, MD8, Richard Stone, MD9, Omar Abdel-Wahab, MD10, Martin Tallman, MD11, Jae H Park, MD12
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Yale Cancer Center, New Haven, Connecticut, United States
4 Beth Israel Deaconess Cancer Center, Boston, Massachusetts, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 National Cancer Institute, Bethesda, Maryland, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Sloan Kettering Institute, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Background: The BRAF V600E mutation occurs in almost all patients with classical hairy cell leukemia (HCL) and enables therapeutic targeting by BRAF inhibition. The BRAF inhibitor, vemurafenib (VEM), is effective in relapsed/refractory HCL, and efficacy is further enhanced when combined with an anti-CD20 antibody. This provides strong rationale for VEM-based therapy as a frontline chemotherapy-free option to avoid risks of myelosuppression and potential malignancies associated with purine analogs. We conducted a phase II, single-arm, multicenter study of VEM plus the anti-CD20 antibody, obinutuzumab (OBIN), in patients with previously untreated HCL (NCT03410875) and reported initial results at median 35 months follow-up (Park et al. NEJM Evid 2023). We now present the long-term efficacy and safety data at 5 years after study completion.

Methods:
30 adults with untreated HCL meeting at least one treatment criteria (absolute neutrophil count [ANC] <1k/uL, hemoglobin [Hgb] <10g/dL, or platelets [Plt] <100k/uL) were enrolled. Treatment consisted of 4 cycles (28 days each) of VEM 960mg PO BID with VEM plus OBIN 1000mg IV in cycles 2-4 (days 1, 8, and 15 of cycle 2; day 1 of cycles 3-4). Patients underwent disease assessments by bone marrow (BM) evaluation after cycle 4. CR was defined by resolution of cytopenias (ANC ≥1k/uL, Hgb ≥10g/dL, or Plt ≥100k/uL) and absence of HCL in the BM and peripheral blood (PB) by nonimmunologic stains. MRD was considered negative if HCL was undetectable by BM multiparameter flow cytometry and immunohistochemistry. Primary endpoint was CR rate; secondary endpoints included safety, MRD-negativity rate, and overall survival (OS).

Results:
Median age was 54 years (range 28-82); patients included 27 men and 3 women. For those with ethnicity/race data, 2/26 were Hispanic, 1/27 were Asian, and 26/27 were White. At baseline, mean BM involvement by HCL was 66% (range 20-90), 53% had splenomegaly, and median PB counts were: ANC 0.8k/uL (range 0.0-2.6), Hgb 12.3g/dL (range 7.0-15.0), and Plt 83k/uL (range 21-153). For 27/30 patients who completed study therapy, all achieved CR with 26/27 MRD-negative; CR rate was 90% in the intention-to-treat (ITT) analysis. Three patients discontinued the study early due to grade (Gr) 1 verrucous hyperplasia, Gr2 rash, and Gr4 pneumonia. As previously reported in detail, one patient who withdrew from the study early due to pneumonia died of multifocal pneumonia. Common treatment-related adverse events included rash (90%; 63% Gr3), arthralgia (80%; 10% Gr3), pruritis (43% Gr1-2 only), and fatigue (40% Gr1-2 only). Drug-related cytopenias were limited to transient Gr3-4 neutropenia (5/30) and B cell aplasia (5/9 evaluable patients). Febrile neutropenia occurred in 2 patients; there were no therapy-related infections. Among 4 patients with B cell aplasia and follow-up lymphocyte subset data, all recovered B cells to >20/uL by 14-38 (median 21) months. Hypogammaglobulinemia <500mg/dL occurred in 1/14 evaluable patients without need for IVIG. At median follow-up of 71 months (95% confidence interval [CI] 68-78), all 27 responders remain in remission. For 18 patients with evaluable data, the latest PB counts at median 69 months (range 10-98) were within normal limits with median ANC 3.8k/uL (range 2.3-7.5), Hgb 15.2g/dL (range 12.6-16.8), and Plt 194k/uL (range 156-313). Dysplastic nevi were found in one patient undergoing regular skin exams for pre-existing psoriasis. Overall, there were no persistent or late therapy-related skin, joint, or infectious toxicities with long-term follow-up and no evidence of new second malignancies since the last report. There have been no new deaths, and estimated OS in the ITT analysis of 30 enrolled patients was 97% (95% CI 79-100).

Conclusions: First-line HCL treatment with the chemotherapy-free VEM/OBIN regimen resulted in a high rate of MRD-negative CR. After over 5 years since study completion, we report that no relapses have occurred in responders and there are no new or delayed toxicities.  The durable long-term remissions are comparable to outcomes of the most used purine analog plus anti-CD20 antibody frontline regimen but with less myelosuppression and febrile neutropenia. Our data indicate that VEM/OBIN is safe, effective, and durable as frontline therapy, and we are actively conducting a randomized, multicenter, phase II study comparing VEM/OBIN and cladribine/rituximab in previously untreated patients with HCL (NCT06561360).

Allison J. Li, MD, PhD: No relevant conflicts of interest to declare.